|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
260,040,000 |
Market
Cap: |
122.27(B) |
Last
Volume: |
1,971,146 |
Avg
Vol: |
1,608,800 |
52
Week Range: |
$323.62 - $456.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 543 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
27,952 |
149,290 |
264,317 |
624,786 |
Total Sell Value |
$12,512,803 |
$62,732,519 |
$104,276,665 |
$212,070,018 |
Total People Sold |
8 |
12 |
14 |
18 |
Total Sell Transactions |
9 |
42 |
65 |
132 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sachdev Amit |
EVP, Chief Patient Officer |
|
2021-04-27 |
4 |
OE |
$86.52 |
$336,044 |
D/D |
3,884 |
44,017 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2021-04-05 |
4 |
AS |
$213.89 |
$361,046 |
D/D |
(1,686) |
35,834 |
|
-10% |
|
Liu Joy |
SVP, General Counsel |
|
2021-03-05 |
4 |
AS |
$207.57 |
$1,078,018 |
D/D |
(5,141) |
8,253 |
|
-6% |
|
Liu Joy |
SVP, General CounselOfficer |
|
2021-03-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,394 |
|
-6% |
|
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-03-01 |
4 |
AS |
$210.13 |
$588,255 |
D/D |
(2,782) |
9,884 |
|
-6% |
|
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-02-26 |
4 |
D |
$212.42 |
$471,148 |
D/D |
(2,218) |
12,666 |
|
- |
|
Arbuckle Stuart A |
EVP, Chief Commercial Officer |
|
2021-02-25 |
4 |
AS |
$211.39 |
$775,989 |
D/D |
(3,634) |
41,103 |
|
-7% |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2021-02-25 |
4 |
AS |
$211.56 |
$765,307 |
D/D |
(3,586) |
40,133 |
|
-7% |
|
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-02-25 |
4 |
AS |
$211.80 |
$230,552 |
D/D |
(1,080) |
14,884 |
|
-7% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2021-02-25 |
4 |
AS |
$211.58 |
$646,139 |
D/D |
(3,028) |
33,589 |
|
-7% |
|
Parini Michael |
EVP, Chief Adm, Leg & BD Off |
|
2021-02-25 |
4 |
AS |
$211.58 |
$646,125 |
D/D |
(3,028) |
30,837 |
|
-7% |
|
Bozic Carmen |
EVP and CMO |
|
2021-02-24 |
4 |
D |
$217.57 |
$67,664 |
D/D |
(311) |
33,264 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2021-02-24 |
4 |
D |
$217.57 |
$630,518 |
D/D |
(2,898) |
63,643 |
|
- |
|
Arbuckle Stuart A |
EVP, Chief Commercial Officer |
|
2021-02-24 |
4 |
D |
$217.57 |
$630,518 |
D/D |
(2,898) |
44,737 |
|
- |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2021-02-24 |
4 |
D |
$217.57 |
$640,961 |
D/D |
(2,946) |
43,719 |
|
- |
|
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-02-24 |
4 |
D |
$217.57 |
$187,980 |
D/D |
(864) |
15,964 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2021-02-24 |
4 |
D |
$217.57 |
$525,649 |
D/D |
(2,416) |
36,617 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2021-02-24 |
4 |
D |
$217.57 |
$119,011 |
D/D |
(547) |
35,226 |
|
- |
|
Parini Michael |
EVP, Chief Adm, Leg & BD Off |
|
2021-02-24 |
4 |
D |
$217.57 |
$525,649 |
D/D |
(2,416) |
33,865 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2021-02-24 |
4 |
D |
$217.57 |
$225,403 |
D/D |
(1,036) |
31,432 |
|
- |
|
Parini Michael |
EVP, Chief Adm, Leg & BD Off |
|
2021-02-18 |
4 |
AS |
$210.08 |
$1,657,556 |
D/D |
(7,825) |
36,281 |
|
-6% |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2021-02-18 |
4 |
AS |
$210.00 |
$1,962,366 |
D/D |
(9,264) |
46,665 |
|
-6% |
|
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-02-18 |
4 |
AS |
$210.05 |
$909,828 |
D/D |
(4,295) |
16,828 |
|
-6% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2021-02-18 |
4 |
AS |
$210.11 |
$1,657,590 |
D/D |
(7,825) |
39,033 |
|
-6% |
|
Arbuckle Stuart A |
EVP, Chief Commercial Officer |
|
2021-02-18 |
4 |
AS |
$210.05 |
$1,657,481 |
D/D |
(7,825) |
47,635 |
|
-6% |
|
3280 Records found
|
|
Page 18 of 132 |
|
|